The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sintilimab (anti-PD-1) plus ifosfamide, carboplatin, and etoposide (ICE) in second-line classical Hodgkin lymphoma (cHL): Results of a multicenter, randomized, controlled, double-blind phase 3 study (ORIENT-21).
 
Peng Liu
No Relationships to Disclose
 
Zhiming Li
No Relationships to Disclose
 
Hong Cen
No Relationships to Disclose
 
Zhengming Jin
No Relationships to Disclose
 
Ai-min Zang
No Relationships to Disclose
 
Xiuhua Sun
No Relationships to Disclose
 
Sujun Gao
No Relationships to Disclose
 
Junning Cao
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Yufu Li
No Relationships to Disclose
 
Xun Lai
No Relationships to Disclose
 
Jishi Wang
No Relationships to Disclose
 
Fei Li
No Relationships to Disclose
 
Shune Yang
No Relationships to Disclose
 
Wenbin Qian
No Relationships to Disclose
 
Hongli Wang
Employment - Innovent Biologics
 
Xiaoyi Tang
Employment - Innovent Biologics
 
Luyin Ding
Employment - Innovent Biologics
 
Hui Zhou
Employment - Innovent Biologics
 
Yuankai Shi
No Relationships to Disclose